Cite
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
MLA
Castillo, Jorge J., et al. “CXCR4 Mutation Subtypes Impact Response and Survival Outcomes in Patients with Waldenström Macroglobulinaemia Treated with Ibrutinib.” British Journal of Haematology, vol. 187, no. 3, Nov. 2019, pp. 356–63. EBSCOhost, https://doi.org/10.1111/bjh.16088.
APA
Castillo, J. J., Xu, L., Gustine, J. N., Keezer, A., Meid, K., Dubeau, T. E., Liu, X., Demos, M. G., Kofides, A., Tsakmaklis, N., Chen, J. G., Munshi, M., Guerrera, M. L., Chan, G. G., Patterson, C. J., Yang, G., Hunter, Z. R., & Treon, S. P. (2019). CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 187(3), 356–363. https://doi.org/10.1111/bjh.16088
Chicago
Castillo, Jorge J., Lian Xu, Joshua N. Gustine, Andrew Keezer, Kirsten Meid, Toni E. Dubeau, Xia Liu, et al. 2019. “CXCR4 Mutation Subtypes Impact Response and Survival Outcomes in Patients with Waldenström Macroglobulinaemia Treated with Ibrutinib.” British Journal of Haematology 187 (3): 356–63. doi:10.1111/bjh.16088.